
Executive Medical Director @EliLillyandCo. Former @FDAOncology.
Washington, DC
Joined June 2013
- Tweets931
- Following174
- Followers877
- Likes11.2K
Timil Patel, MD retweeted
NEW 📣Final FDA Guidance on decentralized #clinicaltrials is out! Covers local labs, imaging, procedures; local healthcare providers; telehealth; informed consent; inv product delivery/accountability; & data mgmt.
#MedTwitter #regulatory #DrugDevelopment
fda.gov/regulatory-informati…
Timil Patel, MD retweeted
Its here!
@US_FDA guidance on Conducting Clinical Trials With Decentralized Elements is out!
Protocols should specify whether
- Telehealth visits is appropriate
- Local health care providers can conduct study visits
fda.gov/regulatory-informati…
Timil Patel, MD retweeted
A @CCR_AACR article highlights how the FDA-AACR Oncology Educational Fellowship helped four alumni develop their career trajectories. Applications for the next class of fellows are open through Aug 1. Learn more:
bit.ly/3SljsIG
#AACRSciencePolicy @timilpatel @HadidiSamer
Timil Patel, MD retweeted
Beginning tomorrow, the Cancer Cabinet that @POTUS created to end cancer as we know it - will host a series of virtual conversations highlighting key actions driving progress on priorities for the #BidenCancerMoonshot.
Join us! whitehouse.gov/cancermoonsho…
Timil Patel, MD retweeted
Career Development Beyond the @FDAOncology-AACR Oncology Educational Fellowship
@CCR_AACR @timilpatel @drjennifergao
oncodaily.com/95185.html
#Cancer #CancerResearch #FDAOncology #AACR #OncoDaily #Oncology
Timil Patel, MD retweeted
Check👇
Reflections and Roadmaps: Career Development Beyond the FDA-AACR Oncology Educational Fellowship @HemOncFellows @FDAOncology @timilpatel @drjennifergao @ChrisChenMD Yasmin Kadry @UAMSMyeloma @CCR_AACR
➡️ aacrjournals.org/clincancerr…
A great program, highly recommended
This Post is from an account that no longer exists. Learn more
Timil Patel, MD retweeted
Online First:
Effect of #ProjectOrbis participation by the Swiss regulator @Swissmedic_ on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis
#cancerdrugs
thelancet.com/journals/lanon…
Timil Patel, MD retweeted
FDA medical oncologist @timilpatel is joining the @DTRAorg gang for a Tues chat to discuss recent #asco24 abstract re: adoption of decentralized trial elements in cancer clinical trials during pandemic. @CTTI_Trials & FDA collected data from research sponsors h/t @akalali 1/n
Timil Patel, MD retweeted
⭐️Honored to meet with the visionary Dr. @realrickpazdur whose insights have always inspired me through all these years. It was such an incredible @ASCO !🏆
Working in oncology clinical trials now is amazing, with advancements in #PrecisionMedicine, immunotherapy, ADCs, & much much more. #ASCO24
Timil Patel, MD retweeted
#CTTI is proud of the contributions Sabrena Mervin-Blake, Sara Bristol Calvert, & Amy Corneli made to this groundbreaking study!
#Covid19 accelerated the use of decentralized trial (DCT) elements in cancer trials. Our study is the first to evaluate DCT elements used in cancer trials submitted to @FDAOncology & led to marketing approval.
Check out our @ASCO abstract - meetings.asco.org/abstracts-…
#ASC024
#Covid19 accelerated the use of decentralized trial (DCT) elements in cancer trials. Our study is the first to evaluate DCT elements used in cancer trials submitted to @FDAOncology & led to marketing approval.
Check out our @ASCO abstract - meetings.asco.org/abstracts-…
#ASC024
How much treatment is enough? @DrRoyHerbstYale from @YaleCancer giving an academic & clinician perspective on perioperative clinical trials - highlighting the importance of patient centricity & bringing all treatment teams to the table.
@FDAOncology /@AACR Workshop.
Timil Patel, MD retweeted
Making an impact while working with visionary leaders - that’s a win win! @FDAOncology
In NSCLC IO trials, the moderate link between ORR & PFS and OS necessitates thorough OS analyses, even if initial PFS results are not promising. This critical measure ensures potential survival benefits are not overlooked. @lobo_goulart @harpreet_md @FDAOncology
NOW OF
An FDA pooled analysis assess correlations of overall response rate and progression-free survival with overall survival in trials of immune checkpoint inhibitors for metastatic non-small-cell lung cancer (NSCLC).
#LCSM
thelancet.com/journals/lanon…
Just released: Report to @POTUS from @PresCancerPanel highlights recommendations in 5 priority areas to accelerate progress towards the #NationalCancerPlan goals. Read the full report here: bit.ly/42T4vBE
3
322
An OCE reunion at Biopharma Congress! A fun & interesting discussion led by Rick Pazdur on misconceptions of the FDA and industry from individuals who know both arenas very well! @FDAOncology @CancerResrch @PrevisionPolicy
Even our most complex trials can be made more patient-centric by moving some assessments closer to where pts live. @ShaalanBeg & @VivekSubbiah offer an insightful perspective on modernizing precision medicine protocols w/ DCT elements. This will be the future!
📣Excited to share our latest paper in @JAMAOnc!📣
🔎@VivekSubbiah and I explore leveraging modern clinical trial tools to enhance access to precision oncology trials. 🔎
🚨Spoiler🚨
It's all about processes, not tech or regulation.
#ClinicalResearch #ClinicalTrials
Timil Patel, MD retweeted
🚨Hot off the press @JAMAOnc @JAMA_current 👉🏼Delighted to share 👉🏼
Modernize Precision Oncology With Decentralized Trial Tools @ShaalanBeg @OncoAlert @oncodaily @OncBrothers jamanetwork.com/journals/jam…





























